Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4656)
All Articles published online
|
Feb 15, 2003 (publication date) through Oct 27, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Wang Z, Ruan YB, Guan Y, Liu SH. Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis. World J Gastroenterol 2003; 9(2): 267-270 [PMID: 12532445 DOI: 10.3748/wjg.v9.i2.267] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Wang Z, Ruan YB, Guan Y, Liu SH. Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis. World J Gastroenterol 2003; 9(2): 267-270 [PMID: 12532445 DOI: 10.3748/wjg.v9.i2.267] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v9/i2/267.htm |
| Number | Citing Articles |
| 1 |
Michael Höpfner, Alexander Huether, Andreas P. Sutter, Viola Baradari, Detlef Schuppan, Hans Scherübl. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochemical Pharmacology 2006; 71(10): 1435 doi: 10.1016/j.bcp.2006.02.006
|
| 2 |
Randa A. Zaghloul, Mamdouh M. El-Shishtawy, Khaled H. Abd El Galil, Mohamed A. Ebrahim, AbdelHamid A. Metwaly, Mohammed M. Al-Gayyar. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma. European Journal of Pharmacology 2015; 746: 353 doi: 10.1016/j.ejphar.2014.11.008
|
| 3 |
Michael Höpfner, Detlef Schuppan, Hans Scherübl. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World Journal of Gastroenterology 2008; 14(1): 1-14 doi: 10.3748/wjg.14.1
|
| 4 |
Mozaffarul Islam, Smita Sharma, Bhavna Kumar, Theodoros N. Teknos. Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncology 2013; 49(8): 778 doi: 10.1016/j.oraloncology.2013.04.003
|
| 5 |
Iliana Fauzi, Nicki Panoskaltsis, Athanasios Mantalaris. Enhanced Hematopoietic Differentiation Toward Erythrocytes from Murine Embryonic Stem Cells with HepG2-Conditioned Medium. Stem Cells and Development 2012; 21(17): 3152 doi: 10.1089/scd.2012.0030
|
| 6 |
Michael Höpfner, Detlef Schuppan, Hans Scherübl. Targeted medical therapy of biliary tract cancer: Recent advances and future perspectives. World Journal of Gastroenterology 2008; 14(46): 7021-7032 doi: 10.3748/wjg.14.7021
|
| 7 |
Jian Zhuge, Ye Luo, Ying-Nian Yu. Heterologous expression of human cytochrome P450 2E1 in HepG2 cell line. World Journal of Gastroenterology 2003; 9(12): 2732-2736 doi: 10.3748/wjg.v9.i12.2732
|
| 8 |
Yulin Yuan, Xuhong Zhou, Jian Song, Xiaoping Qiu, Jun Li, Linfeng Ye, Xiaoping Meng, Dong Xia. Expression and Clinical Significance of Epidermal Growth Factor Receptor and Type 1 Insulin-Like Growth Factor Receptor in Nasopharyngeal Carcinoma. Annals of Otology, Rhinology & Laryngology 2008; 117(3): 192 doi: 10.1177/000348940811700306
|
| 9 |
Dan He, Hongpeng Gong, Jie Pan, Fangchao Zhu, Xiaofen Jiang, Huang Su. Recurrent Non-islet Cell Tumor Hypoglycemia Secondary to Hepatocellular Carcinoma: Case Report and Literature Review. Zeitschrift für Gastroenterologie 2024; 62(05): 752 doi: 10.1055/a-2170-1691
|
| 10 |
Elizabeth Buck, Prafulla C. Gokhale, Susan Koujak, Eric Brown, Alexandra Eyzaguirre, Nianjun Tao, Maryland Rosenfeld-Franklin, Lorena Lerner, M. Isabel Chiu, Robert Wild, David Epstein, Jonathan A. Pachter, Mark R. Miglarese. Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer. Molecular Cancer Therapeutics 2010; 9(10): 2652 doi: 10.1158/1535-7163.MCT-10-0318
|
| 11 |
C. Morace, M. Cucunato, R. Bellerone, G. De Caro, S. Crinò, A. Fortiguerra, F. Spadaro, A. Zirilli, A. Alibrandi, P. Consolo, C. Luigiano, M.L. Resta, O. Ferraù, A. Spadaro. Insulin-like growth factor-II is a useful marker to detect hepatocellular carcinoma?. European Journal of Internal Medicine 2012; 23(6): e157 doi: 10.1016/j.ejim.2012.04.014
|
| 12 |
Agnieszka Adamek, Aldona Kasprzak. Insulin-Like Growth Factor (IGF) System in Liver Diseases. International Journal of Molecular Sciences 2018; 19(5): 1308 doi: 10.3390/ijms19051308
|
| 13 |
Qun-sheng Ji, Mark J. Mulvihill, Maryland Rosenfeld-Franklin, Andrew Cooke, Lixin Feng, Gilda Mak, Matthew O'Connor, Yan Yao, Caroline Pirritt, Elizabeth Buck, Alexandra Eyzaguirre, Lee D. Arnold, Neil W. Gibson, Jonathan A. Pachter. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo
. Molecular Cancer Therapeutics 2007; 6(8): 2158 doi: 10.1158/1535-7163.MCT-07-0070
|
| 14 |
Kun-Peng Fang, Jian-Lin Zhang, Yan-Hong Ren, Ye-Ben Qian. Talin-1 Correlates with Reduced Invasion and Migration in Human Hepatocellular Carcinoma Cells. Asian Pacific Journal of Cancer Prevention 2014; 15(6): 2655 doi: 10.7314/APJCP.2014.15.6.2655
|
| 15 |
J. F. Tsai, J. E. Jeng, L. Y. Chuang, H. L. You, L. Y. Wang, M. Y. Hsieh, S. C. Chen, W. L. Chuang, Z. Y. Lin, M. L. Yu, C. Y. Dai. Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma. Scandinavian Journal of Gastroenterology 2005; 40(1): 68 doi: 10.1080/00365520410009311
|
| 16 |
Mark J. Mulvihill, Elizabeth Buck. Accounts in Drug Discovery. 2010; : 71 doi: 10.1039/9781849731980-00071
|
| 17 |
Daphna Mokady, David Meiri. RhoGTPases – A novel link between cytoskeleton organization and cisplatin resistance. Drug Resistance Updates 2015; 19: 22 doi: 10.1016/j.drup.2015.01.001
|
| 18 |
Sunita Kumari, Arka De, Naveen Kalra, Virendra Singh. Growth Hormone Therapy in Decompensated Cirrhosis: An Open-Label, Randomized Control Trial. American Journal of Gastroenterology 2024; 119(1): 116 doi: 10.14309/ajg.0000000000002300
|
| 19 |
Mandeep Kumar Singh, Bhrigu Kumar Das, Sandeep Choudhary, Deepak Gupta, Umesh K Patil. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. Biomedicine & Pharmacotherapy 2018; 106: 991 doi: 10.1016/j.biopha.2018.06.095
|
| 20 |
Nearmeen M. Rashad, Amal S. El-Shal, Eman H. Abd Elbary, Mohamed H. Abo Warda, Osama Hegazy. Impact of insulin-like growth factor 2, insulin-like growth factor receptor 2, insulin receptor substrate 2 genes polymorphisms on susceptibility and clinicopathological features of hepatocellular carcinoma. Cytokine 2014; 68(1): 50 doi: 10.1016/j.cyto.2014.02.006
|
| 21 |
Miloš Šunderić, Vesna Malenković, Olgica Nedić. Complexes between insulin-like growth factor binding proteins and alpha-2-macroglobulin in patients with tumor. Experimental and Molecular Pathology 2015; 98(2): 173 doi: 10.1016/j.yexmp.2015.03.003
|
| 22 |
Mark J. Mulvihill, Qun-Sheng Ji, Heather R. Coate, Andrew Cooke, Hanqing Dong, Lixin Feng, Kenneth Foreman, Maryland Rosenfeld-Franklin, Ayako Honda, Gilda Mak, Kristen M. Mulvihill, Anthony I. Nigro, Matthew O’Connor, Caroline Pirrit, Arno G. Steinig, Kam Siu, Kathryn M. Stolz, Yingchuan Sun, Paula A.R. Tavares, Yan Yao, Neil W. Gibson. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors. Bioorganic & Medicinal Chemistry 2008; 16(3): 1359 doi: 10.1016/j.bmc.2007.10.061
|
| 23 |
|
| 24 |
Seon-Hee Yim, Yeun-Jun Chung. An Overview of Biomarkers and Molecular Signatures in HCC. Cancers 2010; 2(2): 809 doi: 10.3390/cancers2020809
|
| 25 |
Motawa E. El-Houseini, Mohammed S. Mohammed, Wael M. Elshemey, Tarek D. Hussein, Omar S. Desouky, Anwar A. Elsayed. Enhanced Detection of Hepatocellular Carcinoma. Cancer Control 2005; 12(4): 248 doi: 10.1177/107327480501200407
|
| 26 |
Elizabeth Buck, Mark Mulvihill. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opinion on Investigational Drugs 2011; 20(5): 605 doi: 10.1517/13543784.2011.558501
|
| 27 |
Jennifer Wu, Andrew X Zhu. Targeting insulin-like growth factor axis in hepatocellular carcinoma. Journal of Hematology & Oncology 2011; 4(1) doi: 10.1186/1756-8722-4-30
|
| 28 |
Kimberly Terry, Mehmet Sitki Copur. Molecular Targeted Therapy of Hepatocellular Carcinoma. Journal of Cancer Therapy 2013; 4(02): 426 doi: 10.4236/jct.2013.42A052
|
| 29 |
Stefania Bortoluzzi, Andrea Bisognin, Chiara Romualdi, Gian Antonio Danieli. Novel genes, possibly relevant for molecular diagnosis or therapy of human rhabdomyosarcoma, detected by genomic expression profiling. Gene 2005; 348: 65 doi: 10.1016/j.gene.2004.12.024
|
| 30 |
Li Wang, Min Yao, Zhizhen Dong, Yun Zhang, Dengfu Yao. Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumor Biology 2014; 35(1): 9 doi: 10.1007/s13277-013-1141-0
|
| 31 |
Mai-Huong Thi Ngo, Han-Yin Jeng, Yung-Che Kuo, Josephine Diony Nanda, Ageng Brahmadhi, Thai-Yen Ling, Te-Sheng Chang, Yen-Hua Huang. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. International Journal of Molecular Sciences 2021; 22(4): 1931 doi: 10.3390/ijms22041931
|
| 32 |
Yu-Shik Hwang, Wesley L. Randle, Robert C. Bielby, Julia M. Polak, Athanasios Mantalaris. Enhanced Derivation of Osteogenic Cells from Murine Embryonic Stem Cells After Treatment with HepG2- Conditioned Medium and Modulation of the Embryoid Body Formation Period: Application to Skeletal Tissue Engineering. Tissue Engineering 2006; 12(6): 1381 doi: 10.1089/ten.2006.12.1381
|
| 33 |
Kai Breuhahn, Peter Schirmacher. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World Journal of Gastroenterology 2008; 14(11): 1690-1698 doi: 10.3748/wjg.14.1690
|
| 34 |
Ravinder Kaur, Jatin K. Nagpal, Bibhu R. Das. Polymorphism in IGF-2 as a Surrogate Marker for Predisposition towards Tobacco Chewing-Mediated Oral Cancer. Tumor Biology 2005; 26(3): 147 doi: 10.1159/000086486
|
| 35 |
Michael Höpfner, Detlef Schuppan, Hans Scherübl. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectives. World Journal of Gastroenterology 2008; 14(16): 2461-2473 doi: 10.3748/wjg.14.2461
|
| 36 |
Yuanyuan Ji, Zhidong Wang, Zongfang Li, Na Huang, Haiyan Chen, Baohua Li, Bo Hui. Silencing IGF-II impairs C-myc and N-ras expressions of SMMC-7721 cells via suppressing FAK/PI3K/Akt signaling pathway. Cytokine 2017; 90: 44 doi: 10.1016/j.cyto.2016.10.008
|
| 37 |
Giuseppe Tonini, Vladimir Virzì, Maria Elisabetta Fratto, Bruno Vincenzi, Daniele Santini. Targeted Therapy in Biliary Tract Cancer: 2009 Update. Future Oncology 2009; 5(10): 1675 doi: 10.2217/fon.09.130
|
| 38 |
Weiwei Gui, Yiyi Zhu, Shuiya Sun, Weifen Zhu, Bowen Tan, Hanxin Zhao, Chengxin Shang, Fenping Zheng, Xihua Lin, Hong Li, Wei-Ping Jia. Knockdown of insulin-like growth factor 2 gene disrupts mitochondrial functions in the liver. Journal of Molecular Cell Biology 2021; doi: 10.1093/jmcb/mjab030
|